Kamada/$KMDA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Kamada
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
- Ticker
- $KMDA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 462
- Headquarters
- Rehovot, Israel
- Website
- www.kamada.com
Kamada Metrics
BasicAdvanced
$456M
20.37
$0.38
0.14
$0.42
2.19%
Price and volume
Market cap
$456M
Beta
0.14
52-week high
$9.35
52-week low
$6.55
Average daily volume
117K
Dividend rate
$0.42
Financial strength
Current ratio
4.06
Quick ratio
2.293
Long term debt to equity
0.035
Total debt to equity
0.044
Dividend payout ratio (TTM)
64.81%
Interest coverage (TTM)
26.79%
Profitability
EBITDA (TTM)
41.494
Gross margin (TTM)
40.82%
Net profit margin (TTM)
11.60%
Operating margin (TTM)
14.51%
Effective tax rate (TTM)
16.60%
Revenue per employee (TTM)
$420,000
Management effectiveness
Return on assets (TTM)
4.63%
Return on equity (TTM)
8.40%
Valuation
Price to earnings (TTM)
20.371
Price to revenue (TTM)
2.363
Price to book
5.25
Price to tangible book (TTM)
9.73
Price to free cash flow (TTM)
17.226
Free cash flow yield (TTM)
5.81%
Free cash flow per share (TTM)
0.45
Dividend yield (TTM)
5.41%
Forward dividend yield
2.19%
Growth
Revenue change (TTM)
13.17%
Earnings per share change (TTM)
19.00%
3-year revenue growth (CAGR)
9.58%
10-year revenue growth (CAGR)
9.76%
3-year earnings per share growth (CAGR)
71.40%
10-year earnings per share growth (CAGR)
6.11%
What the Analysts think about Kamada
Analyst ratings (Buy, Hold, Sell) for Kamada stock.
Analyst projections of the future price of Kamada stock.
Bulls say / Bears say
First-half 2026 revenue rose 13% to $100.2 million and adjusted EBITDA rose 14% to $25.7 million, with a 26% margin. Kamada reaffirmed full-year guidance for $200–205 million in revenue and $50–53 million in adjusted EBITDA. (Kamada Pharmaceuticals)
A new three-year plasma supply agreement is expected to generate about $50 million in revenue, adding a contracted source of sales as Kamada ramps up its Texas collection centres. (Kamada Pharmaceuticals)
Recent study findings linked CYTOGAM prophylaxis with better outcomes in high-risk lung transplant recipients. Further evidence could support wider use of the product, although the reported findings are not proof of future sales growth. (Kamada Pharmaceuticals)
KEDRAB’s US business depends on sole distributor Kedrion, while rabies exposure and demand can fluctuate. Kamada also identifies plasma availability and competition as risks to meeting future demand. (Yahoo Finance)
The $50 million plasma contract depends on scaling collection operations, and initial sales are only expected in the fourth quarter of 2026. Any ramp-up or start-up delay could put the first contribution at risk. (Kamada Pharmaceuticals)
Revenue growth may not translate into equally steady profits: product mix can cause gross-margin swings, according to a recent review of Kamada’s results. (Simply Wall St)
Data summarised monthly by Lightyear AI. Last updated on 14 Oct 2026.
Kamada Financial Performance
Revenues and expenses
Kamada Earnings Performance
Company profitability
Upcoming events
No upcoming events
Kamada News
AllArticlesVideos
Funds containing Kamada
Fund name | Fund size | $KMDA weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.03% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.